HONG KONG – As drug developers are racing to find a cure for the new coronavirus, researchers in Hong Kong claim to have made major headway in the development of a vaccine for the virus that has so far killed 132. Yuen Kwok-yung, the chair of infectious diseases at the University of Hong Kong’s (HKU) department of microbiology, said in a press briefing at Hong Kong’s Queen Mary Hospital that his team had successfully isolated the novel virus from the first imported case in Hong Kong. But he said the vaccine still needs months to be tested on animals and an additional year for human trials before it is fit for use.
Adding further evidence about the global threat of the increase of antimicrobial-resistant (AMR) infections and dearth of new antibiotics to treat those conditions, Thomas Cueni, chair of the AMR Industry Alliance, said the findings from the alliance’s newly released report are “a wake-up call” as they estimate current investments in AMR-relevant R&D are not enough to sustain a viable pipeline that will be needed to combat infectious diseases globally.
Salt Lake City-based Co-Diagnostics Inc. has finished the principle design work for a polymerase chain reaction (PCR) screening test for the novel coronavirus that has sickened nearly 3,000 with an acute respiratory illness and killed more than 80 people in Wuhan, China.
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Centers for Disease Control and Prevention, Centers for Medicare and Medicaid Services, Cowen Washington Research Group, European Commission, GE Healthcare
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Avinger, Baylis Medical, Co-Diagnostics, Eptam Precision Solutions, Frazier Healthcare Partners, Fresenius Medical Care, Glaxosmithkline, HG Capital, Intelerad Medical Systems, Investissements Novacap, Myriad Genetics, New Heritage Capital, Oncimmune Holdings, Visquate